Belgian clinical stage biotech company Remynd has extended its series-B round to €24m, with backing from Korys Investments, FPIM, KU Leuven, PMV and BNP Paribas Fortis Private Equity.
Series B takes French food-tech delivery startup’s total funding to USD 105m
Attendees at IPEM 2022 are bracing for challenging fundraising market to continue into 2023
Investor hires James Charalambides from Sixth Street to lead new strategy out of London
Mid-market GP is deploying 2020 Fun IV in primary carve-out from French laboratories company